Name | PDE9-IN-1 |
---|
Description | PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC50 of 8.7 nM[1]. |
---|---|
Related Catalog | |
Target |
PDE9A:8.7 nM (IC50) |
In Vitro | PDE9-IN-1 is excellent selectivity across PDE families[1]. |
In Vivo | PDE9-IN-1 (2.5 and 5.0 mg/kg; Oral administration; daily for 21 days) effectively recovers learning and memory function[1]. Animal Model: Unilateral common carotid artery occlusion (UCCAO) mouse model[1] Dosage: 2.5 and 5.0 mg/kg Administration: Oral administration; daily for 21 days Result: Significantly reduced the day 6 escape latency time and increased the frequency of platform area crossings, and recovered learning and memory function. High dose group possibly improved the escape latency time of mice. |
References |
Molecular Formula | C17H23FN6O2 |
---|---|
Molecular Weight | 362.40 |